This is not terrible news. It was priced for oblivion anyway. The market hated this Frog in charge and he is gone now. Private Equity may swoop fairly quickly.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%